Leucegene
  • Home
  • R & D
  • Achievements
  • Clinic
  • Publications
  • About Us
  • Search
  • Menu Menu

Publications

2022
  • Krosl J, Bordeleau ME, Moison C, MacRae T, Boivin I, Mayotte N, Gracias D, Baccelli I, Lavallée VP, Bisaillon R, Lehnertz B, Mendoza-Sanchez R, Ruel R, Bertomeu T, Coulombe-Huntington J, Boucher G, Noronha N, Pabst C, Tyers M, Gendron P, Lemieux S, Barabé F, Marinier A, Hébert J, Sauvageau G. Vesicular trafficking is a key determinant of the statin response in acute myeloid leukemia. Blood Adv. 2022 Jan 25;6(2):509-514. doi: 10.1182/bloodadvances.2021006047.
  • Lisi V, Blanchard È, Vladovsky M, Audemard E, Ferghaly A, Lemieux S, Hébert J, Sauvageau G, Lavallée VP. Unified gene expression signature of novel NPM1 exon 5 mutations in acute myeloid leukemia. Blood Adv. 2022 Jul 18: bloodadvances.2022007300. doi: 10.1182/bloodadvances.2022007300.
  • Moison C, Spinella JF, Chagraoui J, Lavallée VP, Lehnertz B, Thiollier C, Boivin I, Mayotte N, McRae T, Marinier A, Hébert J, Sauvageau G. HMGA2 expression defines a subset of AML with immature transcriptional signature and vulnerability to G2/M inhibition. Blood Adv. 2022 Jul 7: bloodadvances.2021005828. doi: 10.1182/bloodadvances.2021005828.

2020-2021
  • Lang M, Lemieux S, Hébert J, Sauvageau G, Zawati MH. Legal and Ethical Considerations for the Design and Use of Web Portals for Researchers, Clinicians, and Patients: Scoping Literature Review. Journal of Medical Internet Research. 2021.  vol. 23:11. e26450.
  • Bisaillon R, Moison C, Thiollier C, Krosl J, Bordeleau ME, Lehnertz B, Lavallée VP, MacRae T, Mayotte N, Labelle C, Boucher G, Spinella JF, Boivin I, D’Angelo G, Lavallée S, Marinier A, Lemieux S, Hébert J, Sauvageau G. Genetic characterization of ABT-199 sensitivity in human AML. Leukemia. 2020 Jan;34(1):63-74.doi: 10.1038/s41375-019-0485-x.
  • Simon L, Spinella JF, Yao CY, Lavallée VP, Boivin I, Boucher G, Audemard E, Bordeleau ME, Lemieux S, Hébert J, Sauvageau G. High frequency of germline RUNX1 mutations in patients with RUNX1-mutated AML. Blood. 2020 May 21;135(21):1882-1886. doi: 10.1182/blood.2019003357.

2019
  • Audemard EO, Gendron P, Feghaly A, Lavallée VP, Hébert J, Sauvageau G, Lemieux S. Targeted variant detection using unaligned RNA-Seq reads. Life Sci Alliance. 2019 Aug 19;2(4). pii: e201900336. doi: 10.26508/lsa.201900336.
  • Labelle C, Marinier A, Lemieux S. Enhancing the drug discovery process: Bayesian inference for the analysis and comparison of dose–response experiments. Bioinformatics,2019 Jul 15;35(14):i464-i473. doi: 10.1093/bioinformatics/btz335.
  • Tremblay G, Rousseau B, Marquis M, Beaubois C, Sauvageau G, Hébert J .  Cost-effectiveness analysis of a HMGA2 prognostic test for acute myeloid leukemia in a Canadian setting.  Applied Health Economics and Health Policy. 07 August 2019. doi: 10.1007/s40258-019-00503-5.
  • Baccelli I, Gareau Y, Lehnertz B, Gingras S, Spinella JF, Corneau S, Mayotte N, Girard S, Frechette M, Blouin-Chagnon V, Leveillé K, Boivin I, MacRae T, Krosl J, Thiollier C, Lavallée VP, Kanshin E, Bertomeu T, Coulombe-Huntington J, St-Denis C, Bordeleau ME, Boucher G, Roux PP, Lemieux S, Tyers M, Thibault P, Hébert J, Marinier A, Sauvageau G. Mubritinib Targets the Electron Transport Chain Complex I and Reveals the Landscape of OXPHOS Dependency in Acute Myeloid Leukemia. Cancer Cell. 2019 Jul 8;36(1):84-99.e8. doi: 10.1016/j.ccell.2019.06.003.
  • Moison C, Lavallée VP, Thiollier C, Lehnertz B, Boivin I, Mayotte N, Gareau Y, Fréchette M, Blouin-Chagnon V, Corneau S, Lavallée S, Lemieux S, Marinier A, Hébert J, Sauvageau G.  Complex karyotype AML displays G2/M signature and hypersensitivity to PLK1 inhibition. Blood Adv.2019 Feb 26;3(4):552-563. doi: 10.1182/bloodadvances.2018028480.

2018
  • Marquis M#, Beaubois C#, Lavallée V-P, Abrahamowicz M, Danieli C, Lemieux S, Ahmad I, Wei A, Ting SB, Fleming S, Schwarer A, Grimwade D, Grey W, Hills RK, Vyas P, Russell N, Sauvageau G, and Hébert J. High expression of HMGA2 independently predicts poor clinical outcomes in acute myeloid leukemia. Blood Cancer J. 2018 Jul 19;8(8):68. doi: 10.1038/s41408-018-0103-6. #, equal contributions.
  • Audemard E, Gendron P, Lavallée VP, Hébert J,  Sauvageau G,  Lemieux S. Target variant detection in leukemia using unaligned RNA-Seq reads. Online on bioRxiv.                             
  • Lavallée VP, Chagraoui J, MacRae T, Marquis M, Bonnefoy A , Krosl J , Lemieux S , Marinier A , Pabst C, Rivard GE, Hebert J, Sauvageau G. Transcriptomic landscape of acute promyelocytic leukemia reveals aberrant surface expression of the platelet aggregation agonist Podoplanin. Leukemia 2018 Feb 23. doi: 10.1038/s41375-018-0069-1

2017
  • Lehnertz B, Zhang YW, Boivin I, Mayotte N, Tomellini E, Chagraoui J, Lavallée VP, Hébert J, Sauvageau G. H3K27M/I mutations promote context-dependent transformation in acute myeloid leukemia with RUNX1alterations. Blood 2017 Nov 16;130(20):2204-2214. doi: 10.1182/blood-2017-03-774653. Epub 2017 Aug 30.
  • Simon L, Lavallée VP, Bordeleau ME, Krosl J , Baccelli I, Boucher G , Lehnertz B, Chagraoui J, MacRae T, Ruel R , Chantigny YA , Lemieux S, Marinier A, Hébert J, Sauvageau G. Chemogenomic landscape of RUNX1-mutated AML reveals importance of RUNX1 allele dosage in genetics and glucocorticoid sensitivity.  Clinical Cancer Research 2017 Nov 15;23(22):6969-6981. doi: 10.1158/1078-0432.CCR-17-1259. Epub 2017 Aug 30.
  • Lemieux S, Sargeant T, Laperrière D, Ismail H, Boucher G, Rozendaal M, Lavallée VP, Ashton-Beaucage D, Wilhelm B, Hébert J, Hilton DJ, Mader S, Sauvageau G. MiSTIC, an integrated platform for the analysis of heterogeneity in large tumour transcriptome datasets. Nucleic Acids Res. 2017 Jul 27;45(13):e122. doi: 10.1093/nar/gkx338.
  • Richard-Carpentier G, Sauvageau G.  Bringing a Leukemic Stem Cell Gene Signature into Clinics: Are We There Yet?   Cell Stem Cell. 2017 Mar 2;20(3):300-301. doi: 10.1016/j.stem.2017.02.010.
  • Baccelli I, Krosl J, Boucher G, Boivin I, Lavallée VP, Hébert J, Lemieux S, Marinier A, Sauvageau G. A novel approach for the identification of efficient combination therapies in primary human acute myeloid leukemia specimens.  Blood Cancer J. 2017 Feb 17;7(2):e529. doi: 10.1038/bcj.2017.10.

2016
  • Maiga A, Lemieux S, Pabst C, Lavallée VP, Bouvier M, Sauvageau G, Hébert J. (2016). Transcriptome analysis of G protein-coupled receptors in distinct genetic subgroups of acute myeloid leukemia: identification of potential disease-specific targets. Blood Cancer J. 2016 Jun 3;6(6):e431. doi: 10.1038/bcj.2016.36.
  • Lavallée VP, Krosl J, Lemieux S, Boucher G, Gendron P, Pabst C, Boivin I, Marinier A, Guidos CJ, Meloche S, Hébert J, Sauvageau G. (2016). Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors. Blood. 2016 Jun 16;127(24):3054-61. doi: 10.1182/blood-2016-03-705053. Epub 2016 Mar 31.
  • Lavallée VP, Lemieux S, Boucher G, Gendron P, Boivin I, Armstrong RN, Sauvageau G, Hébert J. (2016). RNA-sequencing analysis of core binding factor AML identifies recurrent ZBTB7A mutations and defines RUNX1-CBFA2T3 fusion signature. Blood. 2016 May 19;127(20):2498-501. doi: 10.1182/blood-2016-03-703868. Epub 2016 Mar 11.
  • Lavallée VP, Lemieux S, Boucher G, Gendron P, Boivin I, Girard S, Hébert J, Sauvageau G. (2016). Identification of MYC mutations in acute myeloid leukemias with NUP98-NSD1 translocations Leukemia. Leukemia. 2016 Feb 9. doi: 10.1038/leu.2016.19.
  • Pabst C, Bergeron A, Lavallée VP, Yeh J, Gendron P, Norddahl GL, Krosl J, Boivin I, Deneault E, Simard J, Imren S, Boucher G, Eppert K, Herold T, Bohlander SK, Humphries K, Lemieux S, Hébert J, Sauvageau G, Barabé F. (2016). GPR56 identifies primary human acute myeloid leukemia cells with high repopulating potential in vivo. Blood. 2016 Apr 21;127(16):2018-27. doi: 10.1182/blood-2015-11-683649. Epub 2016 Feb 1.
  • Shifman AR, Johnson RM, Wilhelm BT. (2016). Cascade: an RNA-seq visualization tool for cancer genomics. BMC Genomics. 2016 Jan 25;17(1):75. doi: 10.1186/s12864-016-2389-8.

2015
  • Kleiderman E, Avard D, Besso A, Ali-Khan S, Sauvageau G, Hébert J (2015). Disclosure of incidental findings in cancer genomic research: investigators’ perceptions on obligations and barriers. Clin. Genet. 88(4): 320-6.
  • Lavallée VP, Baccelli I, Krosl J, Wilhelm B, Barabé F, Gendron P, Boucher G, Lemieux S, Marinier A, Meloche S, Hébert J, Sauvageau G (2015). The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias. Nat. Genet. 47:1032-1037.
  • Lavallé VP, Gendron P, Lemieux S, D’Angelo G, Hébert J, Sauvageau G. (2015). EVI1-rearranged acute myeloid leukemias are characterized by distinct molecular alterations. Blood. 125(1): 140-3.

2014
  • Lehnertz B, Pabst C, Su L, Miller M, Liu F, Yi L, Zhang RG, Krosl J, Yung E, Kirschner J, Rosten P, Underhill TM, Jin J, Hébert J, Sauvageau G, Humphries RK, Rossi FM. (2014). The methyltransferase G9a regulates HoxA9-dependent transcription in AML. Genes Dev. 28(4): 317-27.
  • Pabst C, Krosl J, Fares I, Boucher G, Ruel R, Marinier A, Lemieux S, Hébert J, Sauvageau G. (2014). Identification of small molecules that support human leukemia stem cell activity ex vivo. Nat. Methods. 11(4): 436-42.
  • Lavallée VP, Boivin I, Armstrong RN, Lemieux S, Hébert J, Sauvageau G. (2014, June). AML with EVI1 Rearrangements Are Characterized By Frequent SF3B1 And IKZF1 Mutations. 19th Congress of European Hematology Association (EHA), Milan, Italy. Published in Haematologica. 99(supp 1): 13.
  • Lavallée VP, Boivin I, Armstrong RN, Lemieux S, Gendron P, Hébert J, Sauvageau G. (2014, Aug). AML with EVI1 rearrangements are characterized by SF3B1 and IKZF1 mutations and distinct expression of MECOM isoforms. 43rd Annual Scientific Meeting of the International Society for Experimental Hematology (ISEH), Montreal, Canada. Published in Exp. Hematol. 42(8): S44.
  • Lehnertz B, Boucher G, Mallard W, Gendron P, Hébert J, Lemieux S, Rinn J, Sauvageau G. (2014, Aug). Long non-coding RNA expression in normal and leukemic human blood samples: Towards the identification of novel biomarkers and hematopoietic regulators. 43rd Annual Scientific Meeting of the International Society for Experimental Hematology (ISEH), Montreal, Canada. Published in Exp. Hematol. 42(8): S44.
  • Celton M, Forest A, Gosse G, Lemieux S, Hébert J, Sauvageau G, Wilhelm BT. (2014). Epigenetic regulation of GATA2 and its impact on normal karyotype acute myeloid leukemia. Leukemia. 28(8): 1617-26.

2013
  • Macrae T, Sargeant T, Lemieux S, Hébert J, Deneault E, Sauvageau G. (2013). RNA-Seq Reveals Spliceosome and Proteasome Genes as Most Consistent Transcripts in Human Cancer Cells. PLoS One 8(9):e72884.
  • Lavallée VP, Gendron P, Boucher G, Arteau M, Wilhelm BT, Lemieux S, Hébert J, Sauvageau G. (2013, Nov). NGS-Based Detection Of Multiple RAS-Mutated Clones In MLL-Rearranged Leukemias Suggests Strong Oncogenic Collaboration. 55th Annual Meeting of the American Society of Hematology (ASH), New Orleans, USA. Published in Blood. 122(21): 744.
  • Sauvageau G, Pabst C, Lemieux S, Hébert J, Krosl J. (2013, Nov). Novel Targeting Strategies for Leukemia-Initiating Cells in Myeloid Neoplasms. 55th Annual Meeting of the American Society of Hematology (ASH), New Orleans, USA. Published in Blood. 122(21): SCI-27.
  • Black L, Avard D, Zawati MH, Knoppers BM, Hébert J, Sauvageau G. (2013). Funding considerations for the disclosure of genetic incidental findings in biobank research. Clin. Genet. 84(5):397-406.

2012
  • Simon C, Chagraoui J, Krosl J, Gendron P, Wilhelm B, Lemieux S, Boucher G, Chagnon P, Drouin S, Lambert R, Rondeau C, Bilodeau A, Lavallée S, Sauvageau M, Hébert J, Sauvageau G. (2012). A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia. Genes Dev. 26:651-6.

Copyright © 2004 - 2021 Sauvageau Laboratory. All Rights Reserved.
Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.

OKLearn more

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Google Analytics Cookies

These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.

If you do not want that we track your visit to our site you can disable tracking in your browser here:

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Other cookies

The following cookies are also needed - You can choose if you want to allow them:

Accept settingsHide notification only